Glioblastoma entities express subtle differences in molecular composition and response to treatment

Oncology Reports

Volumn 38, Issue 3, 2017, Pages 1341-1352

  Balça Silva, Joana ^a,b,c   Matias, Diana ^c,d   Do Carmo, Anália ^a,e   Dubois, Luiz Gustavo ^c   Gonçalves, Ana Cristina ^a,b,e   Girao, Henrique ^a,b   Silva Canedo, Nathalie Henriques ^d   Correia, Ana Helena ^d   De Souza, Jorge Marcondes ^d   Sarmento Ribeiro, Ana Bela ^a,b,e   Lopes, Maria Celeste ^a,f   Moura Neto, Vivaldo ^c  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c Instituto Estadual Do Cérebro Paulo Niemeyer IECPN   (Brazil)

^d FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^e UNIVERSITY OF COIMBRA   (Portugal)

^f UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Cell motility; Cellular heterogeneity; Chemotherapeutic resistance; Glioblastoma; Glioma cancer stem like cells

Indexed keywords

F ACTIN; MULTIDRUG RESISTANCE PROTEIN; PROTEIN KINASE C; TAMOXIFEN; TEMOZOLOMIDE; DACARBAZINE; MULTIDRUG RESISTANCE PROTEIN 1;

ARTICLE; CANCER MORPHOLOGY; CELL CYCLE ARREST; CELL DEATH; CELL ISOLATION; CELL MIGRATION; CONTROLLED STUDY; ENZYME ACTIVATION; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENE OVEREXPRESSION; GENETIC HETEROGENEITY; GLIOBLASTOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; APOPTOSIS; ASTROCYTOMA; CANCER GRADING; CELL CYCLE CHECKPOINT; CELL MOTION; CELL PROLIFERATION; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

APOPTOSIS; ASTROCYTOMA; ATP-BINDING CASSETTE, SUB-FAMILY B, MEMBER 1; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DACARBAZINE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC HETEROGENEITY; GLIOBLASTOMA; HUMANS; NEOPLASM GRADING; PROTEIN KINASE C; SIGNAL TRANSDUCTION; TAMOXIFEN;

EID: 85026351572     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2017.5799     Document Type: Article

References (48)

1. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P and Ellison DW: The 2016 World Health Organization Classification of Tumors of the Central Nervous System: A summary. Acta Neuropathol 131: 803-820, 2016.
2. Stupp R, Hegi ME, Gilbert MR and Chakravarti A: Chemoradiotherapy in malignant glioma: Standard of care and future directions. J Clin Oncol 25: 4127-4136, 2007.
3. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996, 2005.
4. Lima FRS, Kahn SA, Soletti RC, Biasoli D, Alves T, da Fonseca A C, Garcia C, Romão L, Brito J, Holanda-Afonso R, et al: Glioblastoma: Therapeutic challenges, what lies ahead. Biochim Biophys Acta 1826: 338-349, 2012.
5. Huse JT, Holland E and DeAngelis LM: Glioblastoma: Molecular analysis and clinical implications. Annu Rev Med 64: 59-70, 2013.
6. Balça-Silva J, Matias D, do Carmo A, Girão H, Moura-Neto V, Sarmento-Ribeiro AB and Lopes MC: Tamoxifen in combination with temozolomide induce a synergistic inhibition of PKC-pan in GBM cell lines. Biochim Biophys Acta 1850: 722-732, 2015.
7. Carmo A, Carvalheiro H, Crespo I, Nunes I and Lopes MC: Effect of temozolomide on the U-118 glioma cell line. Oncol Lett 2: 1165-1170, 2011.
8. do Carmo A, Patricio I, Cruz MT, Carvalheiro H, Oliveira CR and Lopes MC: CXCL12/CXCR4 promotes motility and proliferation of glioma cells. Cancer Biol Ther 9: 56-65, 2010.
9. Hattermann K and Mentlein R: An infernal trio: The chemokine CXCL12 and its receptors CXCR4 and CXCR7 in tumor biology. Ann Anat 195: 103-110, 2013.
10. Zhou J, Atsina KB, Himes BT, Strohbehn GW and Saltzman WM: Novel delivery strategies for glioblastoma. Cancer J 18: 89-99, 2012.
11. Safa AR, Saadatzadeh MR, Cohen-Gadol AA, Pollok KE and Bijangi-Vishehsaraei K: Glioblastoma stem cells (GSCs) epigenetic plasticity and interconversion between differentiated non-GSCs and GSCs. Genes Dis 2: 152-163, 2015.
12. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, et al; European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10: 459-466, 2009.
13. Thirant C, Bessette B, Varlet P, Puget S, Cadusseau J, Tavares SR, Studler JM, Silvestre DC, Susini A, Villa C, et al: Clinical relevance of tumor cells with stem-like properties in pediatric brain tumors. PLoS One 6: e16375, 2011.
14. Bogush T, Dudko E, Bogush E, Polotsky B, Tjulandin S and Davydov M: Tamoxifen non-estrogen receptor mediated molecular targets. Oncol Rev 6: e15, 2012.
15. Kahn SA, Biasoli D, Garcia C, Geraldo LH, Pontes B, Sobrinho M, Frauches AC, Romão L, Soletti RC, Assunção FS, et al: Equinatoxin II potentiates temozolomide-and etoposideinduced glioblastoma cell death. Curr Top Med Chem 12: 2082-2093, 2012.
16. F aria J, Romão L, Martins S, Alves T, Mendes FA, de Faria GP, Hollanda R, Takiya C, Chimelli L, Morandi V, et al: Interactive properties of human glioblastoma cells with brain neurons in culture and neuronal modulation of glial laminin organization. Differentiation 74: 562-572, 2006.
17. Linn SC, Giaccone G, van Diest PJ, Blokhuis WM, van der Valk P, van Kalken CK, Kuiper CM, Pinedo HM and Baak JP: Prognostic relevance of P-glycoprotein expression in breast cancer. Ann Oncol 6: 679-685, 1995.
18. Calatozzolo C, Gelati M, Ciusani E, Sciacca FL, Pollo B, Cajola L, Marras C, Silvani A, Vitellaro-Zuccarello L, Croci D, et al: Expression of drug resistance proteins Pgp, MRP1, MRP3, MRP5 and GST-? in human glioma. J Neurooncol 74: 113-121, 2005.
19. Gonçalves AC, Cortesão E, Oliveiros B, Alves V, Espadana A I, Rito L, Magalhães E, Lobão MJ, Pereira A, Nascimento Costa JM, et al: Oxidative stress and mitochondrial dysfunction play a role in myelodysplastic syndrome development, diagnosis, and prognosis: A pilot study. Free Radic Res 49: 1081-1094, 2015.
20. Towbin H, Staehelin T and Gordon J: Immunoblotting in the clinical laboratory. J Clin Chem Clin Biochem 27: 495-501, 1989.
21. Liang CC, Park AY and Guan JL: In vitro scratch assay: A convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc 2: 329-333, 2007.
22. Rittierodt M and Harada K: Repetitive doxorubicin treatment of glioblastoma enhances the PGP expression-a special role for endothelial cells. Exp Toxicol Pathol 55: 39-44, 2003.
23. Borowski E, Bontemps-Gracz MM and Piwkowska A: Strategies for overcoming ABC-transporters-mediated multidrug resistance (MDR) of tumor cells. Acta Biochim Pol 52: 609-627, 2005.
24. Q iu ZK, Shen D, Chen YS, Yang QY, Guo CC, Feng BH and Chen ZP: Enhanced MGMT expression contributes to temozolomide resistance in glioma stem-like cells. Chin J Cancer 33: 115-122, 2014.
25. Hegi ME, Diserens A-C, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352: 997-1003, 2005.
26. He W, Liu R, Yang SH and Yuan F: Chemotherapeutic effect of tamoxifen on temozolomide-resistant gliomas. Anticancer Drugs 26: 293-300, 2015.
27. Couldwell WT, Hinton DR, He S, Chen TC, Sebat I, Weiss MH and Law RE: Protein kinase C inhibitors induce apoptosis in human malignant glioma cell lines. FEBS Lett 345: 43-46, 1994.
28. Zhang W, Couldwell WT, Song H, Takano T, Lin JH and Nedergaard M: Tamoxifen-induced enhancement of calcium signaling in glioma and MCF-7 breast cancer cells. Cancer Res 60: 5395-5400, 2000.
29. O'Brian CA, Liskamp RM, Solomon DH and Weinstein IB: Inhibition of protein kinase C by tamoxifen. Cancer Res 45: 2462-2465, 1985.
30. Kamburo-lu G, Kiratli H, Söylemezo-lu F and Bilgiç S: Clinicopathological parameters and expression of P-glycoprotein and MRP-1 in retinoblastoma. Ophthalmic Res 39: 191-197, 2007.
31. Hui AM, Zhang W, Chen W, Xi D, Purow B, Friedman GC and Fine HA: Agents with selective estrogen receptor (ER) modulator activity induce apoptosis in vitro and in vivo in ER-negative glioma cells. Cancer Res 64: 9115-9123, 2004.
32. Deck JH, Eng LF, Bigbee J and Woodcock SM: The role of glial fibrillary acidic protein in the diagnosis of central nervous system tumors. Acta Neuropathol 42: 183-190, 1978.
33. A ltaner C and Altanerova V: Stem cell based glioblastoma gene therapy. Neoplasma 59: 756-760, 2012.
34. Jackson M, Hassiotou F and Nowak A: Glioblastoma stem-like cells: At the root of tumor recurrence and a therapeutic target. Carcinogenesis 36: 177-185, 2015.
35. Meacham CE and Morrison SJ: Tumour heterogeneity and cancer cell plasticity. Nature 501: 328-337, 2013.
36. Garcia C, Dubois LG, Xavier AL, Geraldo LH, da Fonseca AC, Correia AH, Meirelles F, Ventura G, Romão L, Canedo NH, et al: The orthotopic xenotransplant of human glioblastoma successfully recapitulates glioblastoma-microenvironment interactions in a non-immunosuppressed mouse model. BMC Cancer 14: 923, 2014.
37. Tóth K, Vaughan MM, Peress NS, Slocum HK and Rustum YM: MDR1 P-glycoprotein is expressed by endothelial cells of newly formed capillaries in human gliomas but is not expressed in the neovasculature of other primary tumors. Am J Pathol 149: 853-858, 1996.
38. Sun H, Dai H, Shaik N and Elmquist WF: Drug efflux transporters in the CNS. Adv Drug Deliv Rev 55: 83-105, 2003.
39. Cordon-Cardo C, O'Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR and Bertino JR: Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 86: 695-698, 1989.
40. Schaich M, Kestel L, Pfirrmann M, Robel K, Illmer T, Kramer M, Dill C, Ehninger G, Schackert G and Krex D: A MDR1 (ABCB1) gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients. Ann Oncol 20: 175-181, 2009.
41. Tomaszowski KH, Schirrmacher R and Kaina B: Multidrug efflux pumps attenuate the effect of MGMT inhibitors. Mol Pharm 12: 3924-3934, 2015.
42. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD and Dirks PB: Identification of human brain tumour initiating cells. Nature 432: 396-401, 2004.
43. Diaz A and Leon K: Therapeutic approaches to target cancer stem cells. Cancers (Basel) 3: 3331-3352, 2011.
44. Ortensi B, Setti M, Osti D and Pelicci G: Cancer stem cell contribution to glioblastoma invasiveness. Stem Cell Res Ther 4: 18, 2013.
45. Seymour T, Nowak A and Kakulas F: Targeting aggressive cancer stem cells in glioblastoma. Front Oncol 5: 159, 2015.
46. Cox JL, Wilder PJ, Desler M and Rizzino A: Elevating SOX2 levels deleteriously affects the growth of medulloblastoma and glioblastoma cells. PLoS One 7: e44087, 2012.
47. Callaghan R and Higgins C: Interaction of tamoxifen with the multidrug resistance P-glycoprotein. Br J Cancer 71: 294-299, 1995.
48. Di Cristofori A, Carrabba G, Lanfranchi G, Menghetti C, Rampini P and Caroli M: Continuous tamoxifen and dose-dense temozolomide in recurrent glioblastoma. Anticancer Res 33: 3383-3389, 2013.